Location: Menlo Park, CA
CIK: 0001819257 · Show all filings
Period: Q3 2024 (← Previous) (Next →)
Filing Date: Nov 14, 2024
Total Value: $269M (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| ROIV | ROIVANT SCIENCES LTD | 12,228,465 | $141M | 52.4% | $7.12 | +59.9% | SHS | G76279101 |
| LQDA | LIQUIDIA CORPORATION | 7,182,532 | $71.83M | 26.7% | $13.90 | -21.4% | COM NEW | 53635D202 |
| CGEM | CULLINAN THERAPEUTICS, INC. | 824,705 | $13.81M | 5.1% | $17.74 | 0.0% | COM | 230031106 |
| INSM | INSMED INC | 171,704 | $12.53M | 4.7% | $73.80 | 0.0% | COM PAR $.01 | 457669307 |
| EYPT | EYEPOINT PHARMACEUTICALS | 1,361,979 | $10.88M | 4.0% | $8.78 | 0.0% | COM NEW | 30233G209 |
| NRIX | NURIX THERAPEUTICS, INC. | 325,789 | $7.32M | 2.7% | $22.65 | 0.0% | COM | 67080M103 |
| PHVS | PHARVARIS N.V. | 242,341 | $4.488M | 1.7% | $18.27 | 0.0% | COM | N69605108 |
| NTLA | INTELLIA THERAPEUTICS, INC. | 128,569 | $2.642M | 1.0% | $23.06 | 0.0% | COM | 45826J105 |
| ELVN | ENLIVEN THERAPEUTICS, INC. | 90,572 | $2.313M | 0.9% | $23.16 | 0.0% | COM | 29337E102 |
| OCUL | OCULAR THERAPEUTIX, INC. | 235,498 | $2.049M | 0.8% | $8.24 | 0.0% | COM | 67576A100 |
| — | ASTRIA THERAPEUTICS, INC. | 39,422 | $434K | 0.2% | $11.01 | — | COM | 04635X102 |